期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 -, 期 -, 页码 -出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.2c01348
关键词
-
资金
- NuCana plc
We report NUC-7738 (7a), a 5'-aryloxy phosphoramidate prodrug of 3'-deoxyadenosine, which showed effective anticancer activity against various cancer cell lines, particularly leukemic stem cells. Unlike 3'-dA, the activity of 7a was independent of cellular transporters and kinases, and it exhibited resistance to metabolic deactivation.
3 '-Deoxyadenosine (3 '-dA, Cordycepin, 1) is a nucleoside analogue with anticancer properties, but its clinical development has been hampered due to its deactivation by adenosine deaminase (ADA) and poor cellular uptake due to low expression of the human equilibrative transporter (hENT1). Here, we describe the synthesis and characterization of NUC-7738 (7a), a 5 '-aryloxy phosphoramidate prodrug of 3 '-dA. We show in vitro evidence that 7a is an effective anticancer drug in a panel of solid and hematological cancer cell lines, showing its preferential cytotoxic effects on leukemic stem cells. We found that unlike 3 '- dA, the activity of 7a was independent of hENT1 and kinase activity. Furthermore, it was resistant to ADA metabolic deactivation. Consistent with these findings, 7a showed increased levels of intracellular 3 '-deoxyadenosine triphosphate (3 '-dATP), the active metabolite. Mechanistically, levels of intracellular 3 '-dATP were strongly associated with in vitro potency. NUC-7738 is now in Phase II, dose-escalation study in patients with advanced solid tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据